Binodh De Silva
About Binodh De Silva
Binodh De Silva is the Vice President of Leads Discovery and Optimization at Bristol-Myers Squibb, with over 25 years of experience in the pharmaceutical industry.
Current Position at Bristol-Myers Squibb
Binodh De Silva currently holds the title of Vice President, Leads Discovery and Optimization at Bristol-Myers Squibb in Princeton, NJ. His responsibilities include leading strategic initiatives aimed at discovering and optimizing new drug leads. This role capitalizes on his extensive experience in the pharmaceutical industry, particularly in drug discovery, development, and manufacturing support.
Previous Roles at Bristol-Myers Squibb
Before his current position, Binodh De Silva was the Head of Analytical Strategy & Operations from 2018 to 2019 in New Brunswick, NJ. He also served as the Head of Analytical and BioAnalytical Operations from 2016 to 2018 in Princeton, NJ. Previously, he worked as the Executive Director from 2010 to 2015, where he shaped the strategic direction of various analytical operations within the company.
Experience at Amgen
Prior to joining Bristol-Myers Squibb, Binodh De Silva worked at Amgen as a Director from 2001 to 2010 in Thousand Oaks, CA. In this role, he contributed significantly to the company's pharmaceutical strategies and operations, leveraging his expertise in bioanalytical and CMC analytical disciplines.
Educational Background
Binodh De Silva earned his Ph.D. in Bioanalytical Chemistry from the University of Kansas, where he studied from 1988 to 1995. His educational foundation has been pivotal in supporting his long and accomplished career in the pharmaceutical industry.
Pharmaceutical Industry Expertise
With over 25 years of experience, Binodh De Silva is highly skilled in various facets of the pharmaceutical industry, including discovery, development, and manufacturing support. Known for his capability to build and motivate diverse teams, he focuses on enabling colleagues to achieve their career aspirations. His unique experience covers the entire drug development process, making him a valuable asset in the field.